Piper Sandler analyst Joseph Catanzaro lowered his price target for Aerie Pharmaceuticals to $45 from $48 after looking at script data and conducting a quarterly key opinion leader survey ahead of the company's earnings and 2020 guidance. Aerie's fiscal 2019 sales should easily fall within guidance of $61M-$66M and the midpoint of its fiscal 2020 guidance should fall between $90M-$100M, which leaves little risk of future downward revisions, Catanzaro tells investors in a research note. The analyst keeps an Overweight rating on the shares, noting that while payer access is still rate limiting, key opinion leaders expect their Rhopressa and Rocklatan usage to increase.